Diabetologie und Stoffwechsel 2025; 20(S 01): S40
DOI: 10.1055/s-0045-1807432
Abstracts | DDG 2025
Poster
Posterwalk 4: Klinische Diabetologie Typ-1 & Typ-2 Diabetes

Treatment utilization patterns and characteristics of individuals using tirzepatide for type 2 diabetes in Germany

Authors

  • M Füchtenbusch

    1   Marienplatz, Diabetes Center, Munich, Germany

  • M Kraus

    2   Lilly Deutschland GmbH, Diabetes and Obesity, Bad Homburg vor der Höhe, Germany

  • E Heitmann

    2   Lilly Deutschland GmbH, Diabetes and Obesity, Bad Homburg vor der Höhe, Germany

  • A Zagar

    2   Lilly Deutschland GmbH, Diabetes and Obesity, Bad Homburg vor der Höhe, Germany

  • S Wilhelm

    3   Lilly Deutschland GmbH, Medical Affairs, Bad Homburg vor der Höhe, Germany

  • L Schwarz

    4   Alcedis GmbH, Biometry, Giessen, Germany

  • P Schnecko

    4   Alcedis GmbH, Biometry, Giessen, Germany

  • N Hennies

    5   Lilly Deutschland GmbH, HEOR & RWE, Bad Homburg vor der Höhe, Germany
Further Information
Also available at
 

Objective: To describe treatment utilization patterns and characteristics of individuals with type 2 diabetes (T2D) who are treated with tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, in routine clinical care in Germany.

Methods: This retrospective study used the CompuGroup Medical Healthcare Database which comprises data from electronic medical records of people managed by German office-based physicians (N=4400). Adults (age≥18 years) with a confirmed diagnosis of T2D and a first tirzepatide prescription between 1 July and 30 September 2024 were included. Demographic and clinical characteristics at initiation of tirzepatide treatment, prior T2D treatments, and tirzepatide utilization, were analysed using descriptive statistics.

Results: Data from 2300 first-time tirzepatide users with T2D from 512 office-based physicians were analysed. Physicians included general practitioners (95.7%) (including diabetologists [15.2%]), cardiologists (1.2%), and internists (1.0%). Tirzepatide users had a mean (standard deviation [SD]) age of 60.3 (11.6) years and 45.6% were female. A total of 1264 people (55.0%) had a body mass index≥30 kg/m2. The proportions of people with obesity class I, II and III were 9.0%, 17.2%, and 15.4%, respectively. The mean (SD) HbA1c was 7.8 (1.4)% and 25.2% had been diagnosed with cardiovascular disease. A high proportion of individuals (83.0%) had received prior anti-diabetic treatment including GLP-1 receptor agonists (46.5%) and insulin (28.3%). Tirzepatide was prescribed as the first line of treatment for T2D, or directly after metformin, in 25.5% of new users.

Conclusion: This is the first comprehensive study of the real-world use of tirzepatide among individuals with T2D in Germany. In this population with T2D, most individuals had obesity, an indication for treatment intensification per HbA1c levels, and had received extensive prior anti-diabetic treatment.



Publication History

Article published online:
28 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany